Keros Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · +5.79%
- Market cap
- $197.22M
- 19.62M shares
- Filings
- 538
Q3 2026+6,775.0% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−48.7% FY25 yoy
- $197.22M
- —
- 4.8×
- 0.7×
- -24.48%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $244,061,000 | reported | |
| FY 2024 | 2024-12-31 | $3,550,000 | reported | |
| FY 2023 | 2023-12-31 | $151,000 | reported | |
| FY 2022 | 2022-12-31 | $0 | reported | |
| FY 2021 | 2021-12-31 | $20,100,000 | reported | |
| FY 2020 | 2020-12-31 | $0 | reported | |
| FY 2019 | 2019-12-31 | $10,000,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $375.00M | $375.00M | — | 19.72M sh | −51.4% | 353.9% |
| FY2024 | — | $0.00 | $0.00 | — | 40.56M sh | +12.7% | — |
Segments
Products
LineFY2025ShareChange
License revenue$205.36M84%+6,745.2%
Service and other revenue$38.71M16%+6,937.5%
Service revenue$38.50M16%+1,183.3%
Total$244.06M
Pharmaceutical preparations
Keros Therapeutics, Inc. is the 78th largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
VREOFVireo Growth Inc.$268.8M170.4%25.3%$439.7MLGNDLigand Pharmaceuticals Inc$268.1M60.4%46.4%$6.3BARVNArvinas, Inc.$262.6M0.3%30.8%$493.4MSDGRSchrodinger, Inc.$255.9M23.3%40.4%$2.3BRCUSArcus Biosciences, Inc.$247.0M4.3%142.9%$2.6B
KROSKeros Therapeutics, Inc. (this company)$244.1M6,775.0%35.7%$197.2M
AKBAAkebia Therapeutics, Inc.$236.2M47.5%2.3%$138.5MANABAnaptysbio, Inc$234.6M157.0%5.6%$1.4BPBYIPuma Biotechnology, Inc.$228.4M0.9%13.6%$418.0MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Keros Therapeutics, Inc. · CIK 1664710 · Engraved from SEC EDGAR